Member Contact: Matt Harris
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally.
Clarity’s platform technology allows biopharmaceuticals to be radiolabelled and visualised using PET imaging. The imaging data generated provides powerful information on targeting, clearance and biodistribution of the product, which aids in early drug development. This de-risks the development process and allows making early decisions regarding biopharmaceutical drug candidates. Clarity offers this capability as a service to biopharmaceutical developers worldwide while utilising the expertise to develop its own clinical pipeline.
Clarity utilises its strong imaging capability and proprietary technology to develop radiopharmaceutical based targeted therapeutics. Its in-house drug development program is focused on developing novel targeted therapeutics in oncology using a theranostic approach. Clarity's lead compound, SARTATE™, is entering a Phase 1/2a in neuroendocrine tumour patients in Q1 2017. Clarity will also commence a Phase 0 imaging trial of SARTATE™ in neuroblastoma, an aggressive childhood cancer, in Q1 2017. In other serious diseases, Clarity is developing imaging based companion diagnostics in areas including cardiovascular disease and fibrosis.